Study Name:
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without MK- 2870 in Adult Participants With Resectable Non Small Cell Lung Cancer Not Achieving Pathological Complete Response
Targeted Disease(s):
Lung Cancer
Purpose of Study:
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response.
Study Dates:
April 3, 2024 - February 21, 2034
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Industry
Sponsors:
Merck Sharp & Dohme LLC
Contact:
Phone: 1-888-577-8839
Email: [email protected]
ClinicalTrails.gov Identifier:
NCT06312137
